Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Marth

Showing results (1-10 of 237) with videos related to

Pageof 24
Sort By:
Expert Review of Anticancer Therapy|September 19, 2018
Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case studyChristian Marth
Future Oncology (London, England)|October 13, 2017
Platinum or nonplatinum in recurrent ovarian cancer: that is the questionAndrés Poveda, Christian Marth
Gynakologisch-Geburtshilfliche Rundschau|June 21, 2008
[Adjuvant therapy of breast cancer with trastuzumab]Christine Beneder, Christian Marth
The Lancet. Oncology|July 10, 2003
Why did p53 gene therapy fail in ovarian cancer?Alain G Zeimet, Christian Marth
Cancer Investigation|June 27, 2009
The prognostic impact of bone marrow micrometastases in women with breast cancerStephan Braun, Doris Auer, Christian Marth
Wiener Medizinische Wochenschrift (1946)|May 18, 2010
Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overviewMichael Hubalek, Christine Brantner, Christian Marth
Breast Cancer (Dove Medical Press)|December 25, 2013
Role of pertuzumab in the treatment of HER2-positive breast cancerMichael Hubalek, Christine Brantner, Christian Marth
Critical Reviews in Oncology/Hematology|August 27, 2019
Hopes and failures in front-line ovarian cancer therapyIrina Tsibulak, Alain G Zeimet, Christian Marth
Cancer Metastasis Reviews|January 8, 2015
Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implicationsIgnace B Vergote, Christian Marth, Robert L Coleman
Wiener Medizinische Wochenschrift (1946)|October 26, 2010
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatmentMichael Hubalek, Christine Brunner, Karin Matthä, et al.
Pageof 24

Showing results (1-10 of 237) with videos related to

Sort By:
Pageof 24
Expert Review of Anticancer Therapy|September 19, 2018
Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case studyChristian Marth
Future Oncology (London, England)|October 13, 2017
Platinum or nonplatinum in recurrent ovarian cancer: that is the questionAndrés Poveda, Christian Marth
Gynakologisch-Geburtshilfliche Rundschau|June 21, 2008
[Adjuvant therapy of breast cancer with trastuzumab]Christine Beneder, Christian Marth
The Lancet. Oncology|July 10, 2003
Why did p53 gene therapy fail in ovarian cancer?Alain G Zeimet, Christian Marth
Cancer Investigation|June 27, 2009
The prognostic impact of bone marrow micrometastases in women with breast cancerStephan Braun, Doris Auer, Christian Marth
Wiener Medizinische Wochenschrift (1946)|May 18, 2010
Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overviewMichael Hubalek, Christine Brantner, Christian Marth
Breast Cancer (Dove Medical Press)|December 25, 2013
Role of pertuzumab in the treatment of HER2-positive breast cancerMichael Hubalek, Christine Brantner, Christian Marth
Critical Reviews in Oncology/Hematology|August 27, 2019
Hopes and failures in front-line ovarian cancer therapyIrina Tsibulak, Alain G Zeimet, Christian Marth
Cancer Metastasis Reviews|January 8, 2015
Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implicationsIgnace B Vergote, Christian Marth, Robert L Coleman
Wiener Medizinische Wochenschrift (1946)|October 26, 2010
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatmentMichael Hubalek, Christine Brunner, Karin Matthä, et al.
Pageof 24